Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD

Clinical Respiratory Journal

Volumn 6, Issue 4, 2012, Pages 248-257

  Bateman, Eric ^a   Feldman, Gregory ^b   Kilbride, Sally ^c   Brooks, Jean ^c   Mehta, Rashmi ^d   Harris, Stephanie ^d   Maden, Claire ^c   Crater, Glenn ^d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b S Carolina Pharmaceutical Research   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Bronchodilator; COPD; Dose ranging; Muscarinic

Indexed keywords

CORTICOSTEROID; DAROTROPIUM BROMIDE; IPRATROPIUM BROMIDE; MUCOLYTIC AGENT; PLACEBO; SALBUTAMOL;

ADULT; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INSPIRATORY CAPACITY; INTENTION TO TREAT ANALYSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORNING DOSAGE; PEAK EXPIRATORY FLOW; PHARMACOKINETICS; PRIORITY JOURNAL; PULSE RATE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPUTUM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VITAL SIGN;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; CONFIDENCE INTERVALS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84866155945     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2011.00278.x     Document Type: Article

References (17)

1. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (updated 2011). Available at: http://www.goldcopd.com (accessed 6 January 2012).
2. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS//ERS position paper. Eur Respir J. 2004;23: 932-46.
3. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek Jr T. A long-term evaluation of once-daily tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19: 217-24.
4. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilania B, Make B, Magussen H. Effects of tiotropium on lung hyperinflation, dyspnoea, and exercise tolerance in COPD. Eur Respir J. 2004;23: 832-40.
5. van Noord JA, Smeets JJ, Custers FLJ, Korducki L, Cornelissen PJG. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J. 2002;19: 639-44.
6. Niewohner DE, Rice K, Cote C, Paulson D, Cooper JA, Korducki L, Cassino C, Kesten S. Prevention of exerbations of chronic obstructive disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator; a randomized trial. Ann Intern Med. 2005;143: 317-26.
7. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelisson PJ. Improved health outcomes in patients with COPD during 1 years treatment with tiotropium. Eur Respir J. 2002;19: 209-16.
8. Laine DI. Long-acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2010;3: 45-53.
9. GSK data in preparation: Cahn etal.
10. Maesen FPV, Smeets JJ, Sledsens TJH, Wald FDM, Cornelissen PJG; on behalf of a Dutch Study group. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J. 1995;8: 1506-13.
11. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation. Am Rev Respir Dis. 1993;148: 1351-7.
12. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest. 2006;130: 1695-703.
13. ® in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2: 559-65.
14. Barnes PJ. Neural control of human airways in health and disease. Am Rev Respir Dis. 1986;34: 1289-14.
15. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23: 1296-310.
16. Vogelmeier C, verkindre C, Cheung D, Galdiz JB, Guclu SZ, Spangenthal S, Overend T, Henley M, Mizutani G, Zeldin RK. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010;23: 438-44.
17. Fogarty C, Hattersley H, Di Scala L, Drollmann A. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med. 2011;105: 337-42.